{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06414954",
            "orgStudyIdInfo": {
                "id": "NMD670-02-0002"
            },
            "secondaryIdInfos": [
                {
                    "id": "2023-507539-40",
                    "type": "OTHER",
                    "domain": "EUCTR"
                }
            ],
            "organization": {
                "fullName": "NMD Pharma A/S",
                "class": "INDUSTRY"
            },
            "briefTitle": "Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis",
            "officialTitle": "A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 3 Dose Levels of NMD670 Over 21 Days in Adult Patients With AChR/MuSK-Ab+ Myasthenia Gravis",
            "acronym": "SYNAPSE-MG",
            "therapeuticArea": [
                "Other"
            ],
            "study": "safety-and-efficacy-of-dose-levels-of-in-adult-patients-with-myasthenia-gravis"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-05-16",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-11-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-11-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-05-10",
            "studyFirstSubmitQcDate": "2024-05-10",
            "studyFirstPostDateStruct": {
                "date": "2024-05-16",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-05",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-08",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "NMD Pharma A/S",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, administered twice a day (BID) for 21 days."
        },
        "conditionsModule": {
            "conditions": [
                "Myasthenia Gravis",
                "Myasthenia Gravis, MuSK"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 84,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "NMD670 high dose",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: NMD670"
                    ]
                },
                {
                    "label": "NMD670 mid dose",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: NMD670"
                    ]
                },
                {
                    "label": "NMD670 low dose",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: NMD670"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "NMD670",
                    "description": "Tablets taken twice a day for 21 days",
                    "armGroupLabels": [
                        "NMD670 high dose",
                        "NMD670 low dose",
                        "NMD670 mid dose"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Tablets taken twice a day for 21 days",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change from baseline to day 21 in QMG total score for NMD670 vs placebo",
                    "description": "Scale goes from 0-36 and higher score indicates worse symptomatology",
                    "timeFrame": "Baseline to day 21"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change from baseline to day 21 in MG-ADL total score for NMD670 vs placebo",
                    "description": "Scale goes from 0-24 and higher score indicates worse symptomatology",
                    "timeFrame": "Baseline to day 21"
                },
                {
                    "measure": "Change from baseline to day 21 in MGC total score for NMD670 vs placebo",
                    "description": "Scale goes from 0-50 and higher score indicate worse symptomatology",
                    "timeFrame": "Baseline to day 21"
                },
                {
                    "measure": "Change from baseline to day 21 in MG-QOL15r for NMD670 vs placebo",
                    "description": "Scale goes from 0-30 and higher score indicate worse quality of life",
                    "timeFrame": "Baseline to day 21"
                },
                {
                    "measure": "Change from baseline to day 21 in Neuro-QoL Fatigue Short Form",
                    "description": "Scale goes from 8-40 and higher score indicate worse symptomalogy",
                    "timeFrame": "Baseline to day 21"
                },
                {
                    "measure": "Incidence of treatment emergent adverse event",
                    "description": "Summarised per treatment",
                    "timeFrame": "Over 21 days of dosing"
                },
                {
                    "measure": "Incidence of serious treatment emergent adverse events",
                    "description": "Summarised per treatment",
                    "timeFrame": "Over 21 days of dosing"
                },
                {
                    "measure": "Incidence of clinically significant abnormalities on physical examinations",
                    "description": "Summarised per treatment",
                    "timeFrame": "Over 21 days of dosing"
                },
                {
                    "measure": "Incidence of clinically significant abnormalities on safety laboratory parameters",
                    "description": "Summarised per treatment",
                    "timeFrame": "Over 21 days of dosing"
                },
                {
                    "measure": "Incidence of clinically significant vital signs abnormalities",
                    "description": "Summarised per treatment",
                    "timeFrame": "Over 21 days of dosing"
                },
                {
                    "measure": "Incidence of clinically significant ECG abnormalities",
                    "description": "Summarised per treatment",
                    "timeFrame": "Over 21 days of dosing"
                },
                {
                    "measure": "Incidence of Suicidal Ideation or Suicidal Behavior",
                    "description": "Summarised per treatment",
                    "timeFrame": "Over 21 days of dosing"
                },
                {
                    "measure": "Incidence of clinically significant abnormalities on opthalmological examinations",
                    "description": "Summarised per treatment",
                    "timeFrame": "From screening (day -28 to day -1) until follow up (day 28)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Participant must be a male or female being 18 to 75 years (both included), at the time of signing the informed consent\n* Diagnosis of MG, MGFA class II, III or IV\n* Documented positive AChR or MuSK antibody test.\n* Participant must be able to swallow tablets\n* Body mass index between 18 and 35 kg/m2, inclusive, at screening, and with a minimum weight of 40 kg\n* Contraceptive use by men and women must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies\n* Participant is capable of and has given signed informed consent\n\nExclusion Criteria:\n\n* Known medical or psychological condition(s) or risk factor that, in the opinion of the Investigator, might interfere with the patient's full participation in the study, pose any additional risk for the patient, or confound the assessment of the patient or outcome of the study\n* Participants with other significant clinical and/or laboratory safety findings that may interfere with the conduction or interpretation of the study\n* Participants that received treatment with an investigational medical product within 30 days (or 5 half-lives of the medication, whichever is longer) prior to Day 1\n* Participants with history of poor compliance with relevant MG therapy\n* Female patients who plan to become pregnant during the study or are currently pregnant or breastfeeding",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "75 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "NMD Pharma A/S",
                    "role": "CONTACT",
                    "phone": "contact@nmdpharma.com",
                    "email": "contact@nmdpharma.com"
                }
            ],
            "locations": [
                {
                    "facility": "Profound Research LLC",
                    "status": "RECRUITING",
                    "city": "Carlsbad",
                    "state": "California",
                    "zip": "92011",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Lupe Sanchez",
                            "role": "CONTACT",
                            "phone": "619-432-0954",
                            "email": "Lupe@profoundresearch.io"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.15809,
                        "lon": -117.35059
                    }
                },
                {
                    "facility": "SFM Clinical Research, LLC",
                    "status": "RECRUITING",
                    "city": "Boca Raton",
                    "state": "Florida",
                    "zip": "33487",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Gabrielle DeMaria",
                            "role": "CONTACT",
                            "phone": "561-939-0333"
                        }
                    ],
                    "geoPoint": {
                        "lat": 26.3669,
                        "lon": -80.13033
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009157",
                    "term": "Myasthenia Gravis"
                },
                {
                    "id": "D000018908",
                    "term": "Muscle Weakness"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009135",
                    "term": "Muscular Diseases"
                },
                {
                    "id": "D000009140",
                    "term": "Musculoskeletal Diseases"
                },
                {
                    "id": "D000020879",
                    "term": "Neuromuscular Manifestations"
                },
                {
                    "id": "D000009461",
                    "term": "Neurologic Manifestations"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000020361",
                    "term": "Paraneoplastic Syndromes, Nervous System"
                },
                {
                    "id": "D000009423",
                    "term": "Nervous System Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000010257",
                    "term": "Paraneoplastic Syndromes"
                },
                {
                    "id": "D000020274",
                    "term": "Autoimmune Diseases of the Nervous System"
                },
                {
                    "id": "D000019636",
                    "term": "Neurodegenerative Diseases"
                },
                {
                    "id": "D000020511",
                    "term": "Neuromuscular Junction Diseases"
                },
                {
                    "id": "D000009468",
                    "term": "Neuromuscular Diseases"
                },
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12112",
                    "name": "Myasthenia Gravis",
                    "asFound": "Myasthenia Gravis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20944",
                    "name": "Muscle Weakness",
                    "asFound": "Myasthenia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M13204",
                    "name": "Paresis",
                    "relevance": "LOW"
                },
                {
                    "id": "M4554",
                    "name": "Asthenia",
                    "relevance": "LOW"
                },
                {
                    "id": "M12092",
                    "name": "Muscular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12097",
                    "name": "Musculoskeletal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M22619",
                    "name": "Neuromuscular Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "M12404",
                    "name": "Neurologic Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M13170",
                    "name": "Paraneoplastic Syndromes",
                    "relevance": "LOW"
                },
                {
                    "id": "M22160",
                    "name": "Paraneoplastic Syndromes, Nervous System",
                    "relevance": "LOW"
                },
                {
                    "id": "M12367",
                    "name": "Nervous System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M22094",
                    "name": "Autoimmune Diseases of the Nervous System",
                    "relevance": "LOW"
                },
                {
                    "id": "M21558",
                    "name": "Neurodegenerative Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M22297",
                    "name": "Neuromuscular Junction Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12411",
                    "name": "Neuromuscular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3973",
                    "name": "Myasthenia Gravis",
                    "asFound": "Myasthenia Gravis",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC05",
                    "name": "Musculoskeletal Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}